Are You Applying the Latest Guidelines for Multiple Myeloma? Experts Discuss Equitable, Evidence-Based Care
Join us for this case-based, interactive on-demand program featuring expert perspectives on treatment for patients with newly diagnosed and relapsed/refractory multiple myeloma.
NCCN Tumor Boards: Treatment Options and Navigating Sequencing of Therapies in Relapsed/Refractory Multiple Myeloma
With the introduction of many new therapies, the management of multiple myeloma is rapidly changing. A uniform treatment approach cannot be applied to all patients.
Managing Post-Treatment Complications for Multiple Myeloma and Acute Lymphocytic Leukemia

As additional, more effective, and novel therapies are added to the repertoire of cancer therapy, there are increasing numbers of cancer survivors, and these survivors are living for longer periods of time from diagnosis.

Management of Multiple Myeloma: Smoldering, Newly Diagnosed, and Relapsed/Refractory Disease

With the introduction of many new therapies, the management of multiple myeloma (MM) is rapidly changing. A uniform treatment approach cannot be applied to all patients.

Optimizing the Use of Bispecific Antibodies in Hematologic Malignancies

Immunotherapy using antibody drug conjugates, immune check point inhibitors, and chimeric antigen receptor (CAR) T-cells has significantly transformed the treatment landscape of relapsed or refractory hematologic malignancies.

CAR T-Cell Therapies in Hematologic Malignancies: Challenges and Strategies

Multiple CAR T-cell therapies are approved for the treatment of certain relapsed or refractory hematologic malignancies with promising clinical outcomes. However, treatment with CAR T-cell therapy is not without risk and can result in severe and potentially fatal toxicities.

Updates to the Management of Multiple Myeloma
With the introduction of many new therapies, the management of multiple myeloma (MM) is rapidly changing. Clinicians would benefit from additional education on the available agents and understanding how to individualize treatment to improve outcomes of patients with MM.
Bispecific Antibodies: A New Frontier in Immunotherapy
The advances in immunotherapy in cancer care are ever-changing and complex. It is integral for nurses to have current knowledge of bispecific antibody therapies in hematologic malignancies and to understand their mechanisms of action and side effect profiles to support optimal patient outcomes.
Bone Disease Management and Infections in Multiple Myeloma
With improvement in treatment options and supportive care, patients with multiple myeloma (MM) are living longer. The majority of patients with MM are at risk for osteolytic bone lesions, osteoporosis, and infections among other complications. The outcomes of patients with MM can be improved by effective management of infections; recognizing and managing side effects of bone modifying therapy; and implementing plans of care to promote health, safety, mobility, and overall improved quality of life.
Tackling Inequities in Multiple Myeloma: Practical Steps for Improving Access and Quality of Care
While there have been significant advancements in the management of multiple myeloma (MM) over the past decade, it is important to recognize that disparities in treatment and survival persist. Identifying patients who may be at risk for health inequity and implementing strategies to improve access and quality of care can help bridge current practice gaps and ensure equitable outcomes for all patients.

Pages

Subscribe to RSS - Multiple Myeloma